Storia in 6 fonti

NewLimit raises $435M Series C, valuation hits $3.1B

The South San Francisco biotech plans to begin its first human trial of a liver cell-reprogramming therapy next year

Raccontata da

Confronto fonti

6 prospettive sulla stessa storia

AI · summaries

qz.comStai leggendo7 h fa

NewLimit raises $435M Series C, valuation hits $3.1B

The South San Francisco biotech plans to begin its first human trial of a liver cell-reprogramming therapy next year

originale

endpoints.news

Timeline cronologica

martedì 2 giugno 2026·statnews.com
Longevity startup NewLimit raises $435 million ahead of first clinical trial
Longevity startup NewLimit plans to launch its first clinical trial of a liver medicine after raising a staggering $435 million in new funding.
martedì 2 giugno 2026·endpoints.news
Anti-aging startup NewLimit raises $435M at $3B+ valuation, eyes clinic in 2027
NewLimit said Tuesday it has raised a $435 million Series C round at a $3.1 billion post-money valuation.

1 g fa

Anti-aging startup NewLimit raises $435M at $3B+ valuation, eyes clinic in 2027

NewLimit said Tuesday it has raised a $435 million Series C round at a $3.1 billion post-money valuation.

Leggi questa versione → originale

cryptobriefing.com1 g fa

NewLimit triples valuation to $3B with $435M funding round

NewLimit, co-founded by Coinbase CEO Brian Armstrong, raises $435M at a $3.1B valuation for its epigenetic reprogramming approach to reversing aging.

Leggi questa versione → originale

statnews.com1 g fa

Longevity startup NewLimit raises $435 million ahead of first clinical trial

Longevity startup NewLimit plans to launch its first clinical trial of a liver medicine after raising a staggering $435 million in new funding.

Leggi questa versione → originale

news.bitcoin.com12 h fa

Coinbase CEO Brian Armstrong's Newlimit Raises $435 Million, Tripling Valuation to $3.1 Billion

Newlimit (biotech Armstrong/Coinbase) chiude Series C $435M, valutazione $3.1B triplicata. Longevity biotech attrae capital massiccio da crypto: aging-reversal diventa frontier seria per tech stack/budget decisions, human trials 2026.

Leggi questa versione → originale

biopharmadive.com22 h fa

NewLimit’s $435M megaround; Lilly’s busy dealmaking week

The anti-aging biotech has secured one of the year’s biggest venture fundings to bring its first drug into testing. Elsewhere, Lilly nabbed a “GLP-2” obesity drug and Praxis shares tumbled.

Leggi questa versione → originale

martedì 2 giugno 2026·

cryptobriefing.com

NewLimit triples valuation to $3B with $435M funding round

NewLimit, co-founded by Coinbase CEO Brian Armstrong, raises $435M at a $3.1B valuation for its epigenetic reprogramming approach to reversing aging.

mercoledì 3 giugno 2026·

biopharmadive.com

NewLimit’s $435M megaround; Lilly’s busy dealmaking week

The anti-aging biotech has secured one of the year’s biggest venture fundings to bring its first drug into testing. Elsewhere, Lilly nabbed a “GLP-2” obesity drug and Praxis…

mercoledì 3 giugno 2026·

news.bitcoin.com

Coinbase CEO Brian Armstrong's Newlimit Raises $435 Million, Tripling Valuation to $3.1 Billion

NewLimit, co-founded by Coinbase CEO Brian Armstrong, raised a $435 million Series C led by Founders Fund, tripling its valuation to $3.1 billion.

mercoledì 3 giugno 2026·

qz.com

NewLimit raises $435M Series C, valuation hits $3.1B

The South San Francisco biotech plans to begin its first human trial of a liver cell-reprogramming therapy next year